XML 62 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments and Fair Value Measurements (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Millions
6 Months Ended 12 Months Ended
Feb. 25, 2020
Jun. 26, 2020
Dec. 27, 2019
Apr. 07, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Contingent Consideration, Liability, Current   $ 34.1    
Contingent Consideration, Liability, Noncurrent   $ 5.0    
4.88% Senior Notes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Debt Instrument, Interest Rate, Stated Percentage       4.875%
Senior Notes | 5.75% Senior Notes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Debt Instrument, Interest Rate, Stated Percentage   5.75%    
Senior Notes | 10.00% Second Lien Senior Notes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Debt Instrument, Interest Rate, Stated Percentage   10.00%    
Level 3 | Other current and non-current assets        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Cash surrender value of life insurance   $ 51.5 $ 51.1  
Level 3 | Recurring | Questcor Pharmaceuticals, Inc.        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Fair value of contingent liability   0.0 24.5  
Level 3 | StrataGraft [Member] | Recurring | Stratatech        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Fair value of contingent liability   30.1 29.0  
Level 3 | MNK-6105 [Member] | Recurring | Ocera [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Fair value of contingent consideration   $ 9.0 15.8  
Level 2 | Debentures | 8.00% Debenture        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Debt Instrument, Interest Rate, Stated Percentage   8.00%    
Level 2 | Debentures | 9.50% Debenture        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Debt Instrument, Interest Rate, Stated Percentage   9.50%    
Level 1 | Senior Notes | 4.75% Senior Notes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Debt Instrument, Interest Rate, Stated Percentage   4.75%    
Level 1 | Senior Notes | 5.75% Senior Notes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Debt Instrument, Interest Rate, Stated Percentage   5.75%    
Level 1 | Senior Notes | 4.88% Senior Notes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Debt Instrument, Interest Rate, Stated Percentage   4.875%    
Level 1 | Senior Notes | 5.50% Senior Notes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Debt Instrument, Interest Rate, Stated Percentage   5.50%    
Level 1 | Senior Notes | 10.00% Second Lien Senior Notes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Debt Instrument, Interest Rate, Stated Percentage   10.00%    
Level 1 | Unsecured Debt | 5.625% Senior Notes        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Debt Instrument, Interest Rate, Stated Percentage   5.625%    
Nuclear Imaging | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Contingent Consideration, Equity Certificates   $ 29.8 18.9  
Indemnification Agreement | Mallinckrodt Baker | Level 1 | Other current and non-current assets        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Restricted Cash and Cash Equivalents   41.4 31.7  
Novartis [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Business Combination, Contingent Consideration, Annual Payments   (25.0)    
Contingent Liabilities | Level 3 | Recurring        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Fair value adjustment   5.7    
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value   39.1 $ 69.3  
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements   $ (25.0)    
Opioid Claimant Trust [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate   63.10% 54.40%  
Warrant, Exercise Price $ 3.15      
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate   0.50% 1.80%  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate   0.00% 0.00%  
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term   7 years 7 months 6 days 7 years 7 months 6 days  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value   $ 2.77 $ 3.45  
Opioid Claimant Trust [Member] | Maximum        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Acquisition of Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners, Quarterly Limit 5.00%      
Other Ownership Interest [Member] | Opioid Claimant Trust [Member] | Maximum        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 19.99%